Nuria Seoane

Nuria Seoane

Auto-generated profile, based on publicly available information

Nuria Seoane

Physiology and Pharmacology of Chronic Diseases (FIFAEC), Center for Research in Molecular Medicine and Chronic Diseases (CiMUS), University of Santiago de Compostela, Santiago de Compostela, Spain; Translational Research in Neurological Diseases (ITEN), Health Research Institute of Santiago de Compostela (IDIS), USC University Hospital Complex (CHUS), SERGAS, 15782 Santiago de Compostela, A Coruña, Spain

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 May 2025 in Biogerontology
Verified
Journal Article
Open access
PDF file
AMAitor Picos Martínez
Aitor Picos Martínez
NSNuria Seoane
Nuria Seoane
Manuel Campos-ToimilManuel Campos-Toimil
Manuel Campos-Toimil
Dolores ViñaDolores Viña
Dolores Viña
The aging vasculature is characterized by endothelial dysfunction, arterial stiffness, and increased susceptibility to vascular pathologies. Central to these changes is the process of cellular senescence, where endothelial and vascular smooth muscle cells lose their replicative and functional capacity and adopt a pro-inflammatory secretory phenotype. This review provides an overview of the key mechanisms underlying vascular senescence, including the p53/p21 and p16/Rb pathways, the senescence-associated secretory phenotype (SASP), and oxidative stress, examines its contribution to cardiovascular diseases in older adults, and highlights emerging therapeutic strategies aimed at delaying or reversing these age-related vascular changes. In vascular cells, DNA damage, oxidative stress, and chronic inflammation associated with aging converge to amplify senescence. Clinically, vascular senescence is linked with hypertension, atherosclerosis, and increased overall cardiovascular risk. Several interventions, ranging from senolytics to lifestyle factors, show promise in mitigating these changes; however, long-term studies are needed. Given that vascular senescence is a pivotal driver of cardiovascular pathology in aging, targeting senescent cells or their secretory phenotype may potentially offer new avenues for preventing or attenuating age-related vascular diseases. This review presents an updated and integrative overview of vascular senescence, connecting fundamental cellular mechanisms with their clinical manifestations and highlighting the most promising therapeutic interventions.

31 July 2021 in Cells
Verified
Journal Article
Open access
PDF file
Dolores ViñaDolores Viña
Dolores Viña
NSNuria Seoane
Nuria Seoane
Elisardo C VasquezElisardo C Vasquez
Elisardo C Vasquez
Manuel Campos-ToimilManuel Campos-Toimil
Manuel Campos-Toimil
The vascular hypothesis used to explain the pathophysiology of Alzheimer’s disease (AD) suggests that a dysfunction of the cerebral microvasculature could be the beginning of alterations that ultimately leads to neuronal damage, and an abnormal increase of the blood–brain barrier (BBB) permeability plays a prominent role in this process. It is generally accepted that, in physiological conditions, cyclic AMP (cAMP) plays a key role in maintaining BBB permeability by regulating the formation of tight junctions between endothelial cells of the brain microvasculature. It is also known that intracellular cAMP signaling is highly compartmentalized into small nanodomains and localized cAMP changes are sufficient at modifying the permeability of the endothelial barrier. This spatial and temporal distribution is maintained by the enzymes involved in cAMP synthesis and degradation, by the location of its effectors, and by the existence of anchor proteins, as well as by buffers or different cytoplasm viscosities and intracellular structures limiting its diffusion. This review compiles current knowledge on the influence of cAMP compartmentalization on the endothelial barrier and, more specifically, on the BBB, laying the foundation for a new therapeutic approach in the treatment of AD.

15 May 2024 in Cells
Verified
Journal Article
Open access
PDF file
NSNuria Seoane
Nuria Seoane
AMAitor Picos Martínez
Aitor Picos Martínez
SMSandra Moraña-Fernández
Sandra Moraña-Fernández
Martina SchmidtMartina Schmidt
Martina Schmidt
ADAmalia Dolga
Amalia Dolga
Dolores ViñaDolores Viña
Dolores Viña
In various neurodegenerative conditions, inflammation plays a significant role in disrupting the blood–brain barrier (BBB), contributing to disease progression. Nitric oxide (NO) emerges as a central regulator of vascular function, with a dual role in inflammation, acting as both a pro- and anti-inflammatory molecule. This study investigates the effects of the NO donor sodium nitroprusside (SNP) in protecting the BBB from lipopolysaccharide (LPS)-induced inflammation, using bEnd.3 endothelial cells as a model system. Additionally, Raw 264.7 macrophages were employed to assess the effects of LPS and SNP on their adhesion to a bEnd.3 cell monolayer. Our results show that LPS treatment induces oxidative stress, activates the JAK2/STAT3 pathway, and increases pro-inflammatory markers. SNP administration effectively mitigates ROS production and IL-6 expression, suggesting a potential anti-inflammatory role. However, SNP did not significantly alter the adhesion of Raw 264.7 cells to bEnd.3 cells induced by LPS, probably because it did not have any effect on ICAM-1 expression, although it reduced VCAM expression. Moreover, SNP did not prevent BBB disruption. This research provides new insights into the role of NO in BBB disruption induced by inflammation.

2 May 2023 in Cells
Verified
Journal Article
Open access
PDF file
OSOksana Shevchuk
Oksana Shevchuk
Svitlana PaliiSvitlana Palii
Svitlana Palii
AVAnastasiia Voitovych
Anastasiia Voitovych
NCNuria Chantada
Nuria Chantada
NSNuria Seoane
Nuria Seoane
Ezequiel AlvarezEzequiel Alvarez
Ezequiel Alvarez
Coronavirus disease (COVID-19) causes various vascular and blood-related reactions, including exacerbated responses. The role of endothelial cells in this acute response is remarkable and may remain important beyond the acute phase. As we move into a post-COVID-19 era (where most people have been or will be infected by the SARS-CoV-2 virus), it is crucial to define the vascular consequences of COVID-19, including the long-term effects on the cardiovascular system. Research is needed to determine whether chronic endothelial dysfunction following COVID-19 could lead to an increased risk of cardiovascular and thrombotic events. Endothelial dysfunction could also serve as a diagnostic and therapeutic target for post-COVID-19. This review covers these topics and examines the potential of emerging vessel-on-a-chip technology to address these needs. Vessel-on-a-chip would allow for the study of COVID-19 pathophysiology in endothelial cells, including the analysis of SARS-CoV-2 interactions with endothelial function, leukocyte recruitment, and platelet activation. “Personalization” could be implemented in the models through induced pluripotent stem cells, patient-specific characteristics, or genetic modified cells. Adaptation for massive testing under standardized protocols is now possible, so the chips could be incorporated for the personalized follow-up of the disease or its sequalae (long COVID) and for the research of new drugs against COVID-19.

15 October 2025 in Life Sciences
Verified
Journal Article
Open access
NSNuria Seoane
Nuria Seoane
AMAitor Picos Martínez
Aitor Picos Martínez
Dolores ViñaDolores Viña
Dolores Viña
Manuel Campos-ToimilManuel Campos-Toimil
Manuel Campos-Toimil
Exchange protein directly activated by cyclic AMP 1 (Epac1), a direct effector of cyclic AMP (cAMP), has been implicated in the regulation of endothelial permeability in peripheral tissues. However, its potential role in protecting the blood-brain barrier (BBB) under inflammatory conditions has not been previously explored. In this study, we evaluated for the first time the impact of selective Epac1 activation on BBB integrity using an in vitro model of brain microvascular endothelial cells (bEnd.3) exposed to lipopolysaccharide (LPS). Cells were cultured in Transwell systems and treated with selective activators or inhibitors of Epac1 and protein kinase A (PKA). Barrier function was assessed through transendothelial electrical resistance (TEER), tight junction protein expression and localization, reactive oxygen species (ROS) production, pro-inflammatory gene expression, and macrophage adhesion assays. Our results show that Epac1 activation significantly prevented the LPS-induced decrease in TEER values, preserved claudin-5 expression, reduced oxidative stress, and stabilized cytoskeletal organization. PKA activation alone did not restore TEER or protect barrier integrity. However, both Epac1 and PKA were required to reduce macrophage adhesion and vascular cell adhesion molecule 1 (VCAM-1) expression, suggesting complementary roles in modulating inflammatory activation. These findings identify Epac1 as a novel modulator of BBB integrity during inflammation and support the therapeutic potential of selectively targeting cAMP signaling pathways to preserve BBB function in neurodegenerative diseases associated with neuroinflammation.